ARWR

Business Context and Reporting Period

Company: Arrowhead Research Corporation (a development-stage nanotechnology holding company).
Reporting Period: Quarterly period ended June 30, 2010 (Form 10-Q).
Business Model: Forms, acquires, and operates subsidiaries commercializing nanotechnologies in biotech and electronics. Key subsidiaries include Calando Pharmaceuticals (oncology drug delivery) and Unidym (carbon nanotube films). The company also holds minority investments in Nanotope and Leonardo Biosystems.

Key Financial Metrics

Key Notes:

• Derivative Liability: A significant non-cash gain of $1,552,228 was recorded due to the change in fair value of a derivative liability (warrants issued in June 2010).
• Discontinued Operations: The company recorded a gain of $409,247 from discontinued operations (sale of Tego Biosciences assets).
• Debt: Includes a $500,000 note payable (Calando) and a $74,845 capital lease obligation.

Material Changes vs. Prior Period

• Revenue Decline: Revenue dropped significantly from $2.63 million in the three months ended June 30, 2009, to $134,000 in the current period. The prior year included $1.75 million in license fees from Calando which did not recur.
• Loss Reduction: Net loss attributable to Arrowhead decreased from $2.53 million (Q2 2009) to $371,000 (Q2 2010). This improvement was primarily driven by the non-cash gain on the derivative liability and reduced operating expenses.
• Expense Reduction: Operating expenses decreased substantially due to cost-cutting measures, including the closure of Unidym's Texas facility, Calando's laboratory closure, and reduced headcount. R&D expenses fell 91% year-over-year for the quarter.
• Cash Position: Cash increased from $2.02 million (Sept 30, 2009) to $8.98 million (June 30, 2010), driven by $12.1 million in proceeds from equity financings.

Outlook, Risks, and Management Commentary

Management Commentary:

• Liquidity: Management anticipates current cash resources ($9.0 million) will fund operations for at least the next 12 months. However, further equity financings or asset sales will likely be necessary.
• Strategy: The company is executing a cash conservation strategy, scaling back development efforts, and seeking partners for technology licensing (e.g., Calando's RONDEL system and Unidym's CNT films).
• Subsidiary Updates: Calando's Phase I trial for CALAA-01 is nearing completion with promising results. Unidym is focusing on joint development agreements for touch-panel markets.

Risks and Contingencies:

• Capital Requirements: As a development-stage company with no significant product revenue, the company is dependent on raising additional capital. Failure to do so could force further curtailment of operations.
• Derivative Liability: The company has a $2.6 million derivative liability related to anti-dilution provisions in warrants, which creates volatility in reported earnings.
• Regulatory and Clinical Risks: Success depends on FDA approvals and clinical trial results for Calando's drug candidates, which are uncertain and costly.
• Intellectual Property: Risks include potential infringement claims and the possibility that Unidym could lose critical patent rights if financial covenants with Rice University are not met.

Investor Verification Checklist

• Cash Runway: Verify the $9.0 million cash balance and the timeline for the next anticipated financing round.
• Derivative Liability Impact: Assess the volatility of the $2.6 million derivative liability and its effect on future earnings reports.
• Calando Clinical Progress: Monitor the completion of the CALAA-01 Phase I trial and the status of partnership negotiations.
• Debt Obligations: Review the terms of the $500,000 Calando convertible note maturing in November 2010.
• Revenue Recurrence: Evaluate the likelihood of recurring revenue from Unidym film sales or Calando licensing, given the sharp decline from prior periods.